ZOLPIDEM TARTRATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Zolpidem is a non-benzodiazepine hypnotic that binds selectively to the benzodiazepine-1 (BZ1) receptor subtype of the GABA-A receptor complex, potentiating GABAergic inhibition. This results in sedative, hypnotic, and anxiolytic effects.
| Metabolism | Hepatic metabolism primarily via CYP3A4, with minor contributions from CYP1A2 and CYP2C9. Metabolites are inactive. Clearance reduced in hepatic impairment. |
| Excretion | Renal (approximately 80% as metabolites, <1% unchanged), fecal (approximately 16%), biliary (minor). |
| Half-life | Terminal elimination half-life is approximately 2.5 hours (range 1.4–4.5 hours) in healthy adults; prolonged to about 2.9–4.5 hours in elderly and up to 9.9 hours in hepatic impairment. Clinical context: short half-life minimizes next-day sedation; accumulation unlikely with once-daily dosing. |
| Protein binding | Approximately 92–95% bound to serum albumin (primarily), with minor binding to α1-acid glycoprotein. |
| Volume of Distribution | 0.54 L/kg (range 0.4–0.8 L/kg) in adults. Clinical meaning: moderate distribution, consistent with lipophilic drug that readily crosses blood-brain barrier. |
| Bioavailability | Oral immediate-release: approximately 70% (range 67–72%) due to first-pass metabolism; sublingual: approximately 75% (higher relative to oral due to avoidance of first-pass); oral spray: approximately 70%; intravenous: 100%. |
| Onset of Action | Oral immediate-release: 15–30 minutes; sublingual: 10–20 minutes; oral spray: 10–20 minutes; intravenous: 1–3 minutes. |
| Duration of Action | Oral immediate-release: 3–4 hours (sleep maintenance variable); extended-release: longer sleep maintenance due to biphasic release; sublingual: ~3 hours; intravenous: ~2 hours. Clinical notes: duration sufficient for sleep initiation; extended-release may improve sleep maintenance; next-day effects possible if <7–8 hours sleep. |
| Molecular Weight | 307.35 |
10 mg orally once daily immediately before bedtime for adults; maximum dose 10 mg per day.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (CrCl <30 mL/min), consider reducing dose to 5 mg due to increased risk of sedation. |
| Liver impairment | For Child-Pugh class A or B: start with 5 mg. For Child-Pugh class C: not recommended due to lack of data and risk of encephalopathy. |
| Pediatric use | Not approved for use in pediatric patients (<18 years). Safety and efficacy not established. |
| Geriatric use | Initiate with 5 mg orally once daily immediately before bedtime; maximum 5 mg per day due to increased sensitivity and risk of falls and cognitive impairment. |
| 1st trimester | Teratogenic effects not established in humans; animal studies show no clear risk. Use only if benefit outweighs risk. |
| 2nd trimester | No adequate studies; consider potential risks and benefits. |
| 3rd trimester | Avoid near term; may cause neonatal respiratory depression, hypotonia, withdrawal symptoms. |
Clinical note
CNS depressants including alcohol increase sedation risk Can cause complex sleep behaviors like sleep-driving.
| Placental transfer | Zolpidem crosses the placenta; detected in cord blood and amniotic fluid. Transfer is rapid and may reach fetal concentrations similar to maternal. |
| Breastfeeding | Zolpidem is excreted into breast milk in low levels. With short-term use of immediate-release formulations, exposure is low, but long-acting forms may accumulate. Monitor infant for sedation, drowsiness, and feeding difficulties. |
■ FDA Black Box Warning
Complex sleep behaviors such as sleep-driving, making phone calls, preparing and eating food, or other activities while not fully awake, with amnesia for the event. Discontinue immediately if such behaviors occur.
| Common Effects | Dizziness |
| Serious Effects |
Hypersensitivity to zolpidem or any componentHistory of complex sleep behaviors (e.g., sleep-driving) while taking zolpidemSevere hepatic impairment (Child-Pugh C)
| Precautions | CNS depression effects (impairs driving and hazardous activities); risk of dependence, abuse, and withdrawal; severe anaphylactic/anaphylactoid reactions; respiratory depression (caution in COPD or sleep apnea); worsening of depression or suicidal ideation; elderly patients at higher risk for falls and cognitive impairment. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - limited data suggest no significant risk when used short-term at lowest effective dose. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Use associated with fetal respiratory depression, hypotonia, and withdrawal symptoms in neonates; risk of floppy infant syndrome. Avoid in third trimester unless essential. |
| Fetal Monitoring | Monitor maternal vital signs and sedation level. In neonates exposed near term, observe for respiratory depression, hypotonia, and withdrawal symptoms for at least 48 hours postpartum. Consider umbilical cord blood levels if overdose suspected. |
| Fertility Effects | No specific human data on fertility impairment. Animal studies have not demonstrated significant reproductive toxicity at therapeutic doses. Theoretical risk of menstrual irregularities due to CNS effects. |
| Avoid high-fat or heavy meals before taking zolpidem as they delay absorption and reduce peak concentrations. Grapefruit juice may increase zolpidem exposure by inhibiting CYP3A4 metabolism, but clinical significance is minimal. No other significant food interactions. |
| Clinical Pearls | Zolpidem tartrate is a non-benzodiazepine sedative-hypnotic that acts as a positive allosteric modulator at GABA-A receptors, specifically alpha-1 subunit. It has rapid onset (15-30 min) and short half-life (2.5-3 hours) making it suitable for sleep-onset insomnia. Avoid with hepatic impairment (Child-Pugh B or C) – reduce dose. Can cause complex sleep behaviors (sleepwalking, driving) – discontinue if occurs. Elderly patients at increased risk of falls and cognitive impairment; use lowest effective dose. Tolerance and dependence can develop; limit use to short-term (≤4 weeks). |
| Patient Advice | Take immediately before bedtime – only if you have 7-8 hours to dedicate to sleep. · Do not take with or after a heavy meal – may delay onset and reduce effect. · Avoid alcohol and other CNS depressants – can cause additive sedation and increased risk of complex behaviors. · Common side effects: daytime drowsiness, dizziness, headache, nausea. · Seek emergency care if you experience sleepwalking, driving while not fully awake, or memory loss. · Do not drive or operate machinery the day after use until you know how the drug affects you. · Do not increase dose or use longer than prescribed – risk of dependence and withdrawal. · Report any allergic reactions (rash, itching, swelling) immediately. · Store at room temperature away from moisture and heat. |